Alzecure: Jan Lundberg proposed as board member

Research Note

2024-04-10

11:29

Redeye endorses today’s news that the nomination committee has proposed Jan Lundberg, Eli Lilly's and AstraZeneca's former head of research, as a new board member of Alzecure. We give a short comment.

FT

Fredrik Thor

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.